Disruption of cholesterol homeostasis in the central nervous system (CNS) has been associated with neurological, neurodegenerative, and neurodevelopmental disorders. The CNS is a closed system with regard to cholesterol homeostasis, as cholesterol-delivering lipoproteins from the periphery cannot pass the blood-brain-barrier and enter the brain. Different cell types in the brain have different functions in the regulation of cholesterol homeostasis, with astrocytes producing and releasing apolipoprotein E and lipoproteins, and neurons metabolizing cholesterol to 24(S)-hydroxycholesterol. We present evidence that astrocytes and neurons adopt different mechanisms also in regulating cholesterol efflux. We found that in astrocytes cholesterol efflux is induced by both lipid-free apolipoproteins and lipoproteins, while cholesterol removal from neurons is triggered only by lipoproteins. The main pathway by which apolipoproteins induce cholesterol efflux is through ABCA1. By upregulating ABCA1 levels and by inhibiting its activity and silencing its expression, we show that ABCA1 is involved in cholesterol efflux from astrocytes but not from neurons. Furthermore, our results suggest that ABCG1 is involved in cholesterol efflux to apolipoproteins and lipoproteins from astrocytes but not from neurons, while ABCG4, whose expression is much higher in neurons than astrocytes, is involved in cholesterol efflux from neurons but not astrocytes. These results indicate that different mechanisms regulate cholesterol efflux from neurons and astrocytes, reflecting the different roles that these cell types play in brain cholesterol homeostasis. These results are important in understanding cellular targets of therapeutic drugs under development for the treatments of conditions associated with altered cholesterol homeostasis in the CNS.
Western blot analysis. The biotinylated ABCA1 was detected using a streptavidin-horseradish peroxidase conjugate. After detection, films were scanned and bands were quantified by densitometry. The sulfo-N-hydroxysuccinimide-biotin purchased from Thermo Fisher Scientific for these studies was characterized as cell membrane-impermeable, accordingly to the company specifications; we verified that this chemical is indeed cell membrane-impermeable by carrying out the following experiment: astrocytes were plated, labeled with sulfo-Nhydroxysuccinimide-biotin and solubilized in lysis buffer in the presence of protease inhibitors as described above; cell lysates were incubated with 200 µl streptavidin beads and mixed by inversion at 4 C for 1 h; in this way, we precipitated all the biotinylated proteins. In order to verify whether intracellular proteins were found among the biotinylated proteins, we separated proteins precipitated with streptavidin beads by SDS-PAGE, transferred to PVDF membranes and then labeled for the intracellular -actin followed by an HRP-conjugated secondary antibody and detected by chemiluminescence; the same membrane was then stripped and re-probed with streptavidin-horseradish peroxidase conjugate. While the labeling of the membranes with -actin antibody did not show any band, the streptavidin-HRP labeling resulted in several bands, corresponding to biotinylated proteins (not shown), indicating that indeed the sulfo-Nhydroxysuccinimide-biotin is cell membrane-impermeable and bind only to cell-surface proteins.
RNA Extraction and Real Time PCR Analysis
RNA was extracted using the TRIzol reagent as per the manufacturer's optimized protocol.
Total RNA concentration, purity and integrity were determined as previously described [19] .
Relative mRNA expressions were determined by RT real-time PCR using ABCA1, ABCG1, and ABCG4 TaqMan® reverse transcription kits and an ABI 7900 HS sequence detection (University of Washington; UW) or a Stratagene MX 3000p system (University of Illinois at Chicago; UIC).
β-Actin was used as reference gene except in the experiments in which cholesterol transporter levels were compared in astrocytes and neurons, when hypoxanthine phosphoribosyltransferase 1 (HPRT1) was used as its levels in neurons and astrocytes were comparable.
Measurement of Exogenous Cholesterol Efflux
Cholesterol efflux was measured as previously described [19] . Briefly, cells labeled with 1 µCi/ml [ 3 H]cholesterol in the presence of 50 µg/ml LDL were treated with 75 mM ethanol, or 1 µM 22(R)-HC plus 9-cisRA for 24 h followed by a 6 h chase in fresh medium supplemented with cholesterol acceptors, apo A-I (10 µg/ml), HDL (50 µg/ml), apo E 3 (15 µg/ml) or astrocyte conditioned medium (ACM 
Cholesterol Synthesis and Endogenous Cholesterol Efflux
Cholesterol synthesis and endogenous cholesterol efflux were measured as previously 
Exposure of Cells to Ethanol
To reduce ethanol evaporation, ethanol incubations were carried out in sealed chambers, which prevent alcohol evaporation, under an atmosphere of 5% CO 2 and 95% air as previously described [19] .
Statistical Analysis
Student's t-test or ANOVA followed by Dunnett's test were used to determine significant differences from controls.
Results
The main objective of this study was to compare mechanisms of cholesterol efflux in primary astrocytes and neurons with particular emphasis on the role of ABC cholesterol transporters.
As the purity of neuronal cultures was critical for the purpose of this study, we took extra care to verify the number of astrocytes present in neuronal cultures by assessing GFAP (astrocytes), NSE (neurons), and Hoechst (nuclei) in neurons prepared using different purification approaches. After 9 days in culture (corresponding to the maximal length of culture in the present experiments) neuronal cultures prepared with an additional step called pre-plating
(in which the suspension of mixed cortex cells was pre-plated for 30 min in flasks coated with 20 µg/ml poly-D-lysine, a concentration too low to allow adequate neuronal attachment, leading to the selective attachment of astrocytes and therefore their removal from the neuronal suspension), consistently contained less than 5% astrocytes (data not shown).
Cholesterol acceptors-mediated cholesterol efflux from astrocytes and neurons
To directly compare cholesterol efflux in neurons and astrocytes, after labeling cells with in contrast, the response of astrocytes and neurons to lipid-poor apolipoproteins was very different. Indeed, apo A-I (10 µg/ml) did not increase cholesterol efflux from neurons, while it induced a 2.15-fold increase in cholesterol efflux from astrocytes. Similarly, apo E 3 (15 µg/ml) increased cholesterol efflux from neurons by only 40%, compared to 260% from astrocytes ( Fig.   1 ). These surprising results suggest that ABCA1 may be involved in cholesterol efflux from astrocytes but not from neurons. Further experiments were then aimed at investigating the role of ABC cholesterol transporters in cholesterol efflux from neurons and astrocytes.
Relative expression of ABCA1, ABCG1, and ABCG4 cholesterol transporters in astrocytes and neurons
Three cholesterol transporters implicated in cholesterol efflux and lipoprotein remodeling have been described in the brain, namely ABCA1, ABCG1, and ABCG4. We compared the relative mRNA expression of these transporters in neurons and astrocytes. We first identified a reference gene that is similarly expressed in neurons and astrocytes. A reference gene commonly used in expression experiments, -actin, was expressed at much higher levels in astrocytes than in neurons; indeed -actin expression in neurons was 0.475 ± 0.023 fold its expression in astrocytes (p<0.001; n=4). Another reference gene, HPRT1, had similar levels of expression in these two cell types (the expression of HPRT1 in neurons was 0.92 ± 0.06 fold its expression in astrocytes; p=0.2921; n=4). For this reason, HPRT1 was used to normalize cholesterol transporter levels when comparing their expression within the same cell type and across astrocytes and neurons. In neurons, ABCA1 was the highest expressed transporter, while ABCG1 and ABCG4 expression was 60% and 63% of ABCA1 respectively (Fig. 2 A) . In astrocytes, ABCA1 was also the highest expressed transporter with ABCG1 and ABCG4 at 45 % and 12% of ABCA1 respectively (Fig. 2 B) . All transporters were expressed to a higher level in neurons than in astrocytes; however, the differential expression was modest for ABCA1
(ratio neurons/astrocytes = 1.46 ± 0.09-fold; p = 0.0682; n=3) and for ABCG1 (1.92 ± 0.05-fold; p = 0.0025; n=3), while expression of ABCG4 was much higher in neurons (7.39 ± 0.47-fold higher; p < 0.001; n=3). The efficiencies of the ABCA1, ABCG1, and ABCG4 primers were very high and very similar to each other (96.3%, 100.3%, and 97.3% respectively), therefore allowing for an accurate determination of the relative levels of expression of these genes in astrocytes and neurons.
Effect of ABCA1 and ABCG1 upregulation on cholesterol efflux in astrocytes and neurons
The role of ABCA1 and ABCG1 cholesterol transporters in cholesterol efflux was evaluated Confirming our previous results, we found that ethanol (75 mM) upregulates expression of ABCA1 and ABCG1 in astrocytes (Fig. 3, inset) . Similarly, in cortical neurons, ethanol upregulates total and membrane-bound (biotinylated) levels of ABCA1 and total levels of ABCG1, as well as ABCA1 and ABCG1 (but not ABCG4) mRNA levels ( Fig. 3 A-E).
Interestingly, the effect of ethanol on the membrane-bound levels of ABCA1 was greater than its effect on total ABCA1 levels; this finding is consistent with our previous observations in astrocytes, indicating that ethanol increases ABCA1 transcription and inhibits ABCA1 degradation at the plasma membrane [19, 29] .
Ethanol has been previously shown to increase cholesterol efflux (measured after incubating , and this was confirmed in the present study (Fig. 4 B) . In contrast, ethanol did not increase cholesterol efflux from cortical neurons (Fig. 4 A) (Fig. 4C) ; however, while ethanol treatments increased the efflux of cholesterol to HDL in astrocytes, this was not the case in neurons (Fig. 4 C) . The small increase in cholesterol efflux observed in astrocytes (but not neurons) after ethanol alone (Fig. 4 C) Experiments with LXR/RXR agonists provided similar results. In both cell types, LXR/RXR agonists increased the protein levels of ABCA1 and ABCG1, as well as the membrane-bound ABCA1, and the levels of ABCA1 and ABCG1 (but not ABCG4) mRNA (Fig. 5 A-E; inset); [19] .
At difference with ethanol, LXR/RXR agonists greatly increased total levels of ABCA1, while membrane-bound ABCA1 was increased to a lower extent, suggesting that different mechanisms may be involved in the effects of these two treatments on ABCA1.
As found with ethanol, LXR/RXR agonists did not affect the efflux of exogenous cholesterol in neurons (Fig. 6 A) , while they did so in astrocytes (Fig. 6 B) , confirming our previous observations [19] . In neurons, efflux of endogenously synthesized cholesterol was stimulated by HDL but not by apo A-I and the incubation with 22(R)-HC in combination with 9-cisRA did not enhance acceptor-induced efflux (Fig. 6C ).
Cholesterol efflux measured by quantifying the distribution of [ Taken together, these data establish that cholesterol content was not modified by 24 h ethanol or 22(R)-HC/9-cisRA treatments preceding the quantification of cholesterol efflux; therefore, the reported changes in cholesterol efflux are not due to preexisting differences in cholesterol content but to actual differences in the rate by which cholesterol is effluxed from cells.
Altogether these results suggest that the upregulation of ABCA1 and ABCG1 by ethanol and by LXR/RXR agonists increases cholesterol efflux from astrocytes but not from neurons; this supports the hypothesis that different mechanisms may regulate cholesterol efflux from these two cell types.
Effect of ABCA1 silencing and inhibition on acceptor-mediated cholesterol efflux from astrocytes and neurons
To further elucidate the role of ABCA1 in cholesterol efflux from astrocytes and neurons, we investigated the effects of ABCA1 inhibition on acceptor-mediated cholesterol efflux in these cell types. First, we down-regulated ABCA1 protein expression using a specific ABCA1 siRNA transfected into astrocytes and neurons (Fig. 7) . Silencing ABCA1 expression in neurons did not affect cholesterol efflux to HDL and apo E in neurons (Fig. 7 A) . In contrast, ABCA1 down-regulation by siRNA in astrocytes significantly decreased cholesterol efflux to several acceptors (apo A-I, apo E 3 , and HDL) (Fig. 7 B) . The transfection of neurons and astrocytes with a nontargeting siRNA did not affect cholesterol efflux (Fig. 7 A, B) . The down-regulation of ABCA1 levels in ABCA1 siRNA-transfected neurons and astrocytes was verified by Western blot analysis (Fig. 7 C, D) .
Additional experiments were carried out using probucol, an inhibitor of ABCA1 activity [32, 33]. Probucol did not affect cholesterol efflux to HDL, apo E, and ACM in neurons (Fig. 7 E) , while cholesterol efflux was significantly inhibited in astrocytes (Fig. 7 F) . These results confirm those obtained with siRNA and suggest that ABCA1 is involved in cholesterol efflux from astrocytes but not from neurons.
While ABCA1 siRNA transfection dramatically decreased ABCA1 levels in astrocytes (Fig. 7 D), its effect on cholesterol efflux was not as pronounced. This fact can be explained by two reasons: first, siRNA prevents the biosynthesis of new ABCA1; it is possible that the remaining ABCA1 is for the most part the membrane-bound, active ABCA1, which may be temporally the last ABCA1 pool to be affected by siRNA inhibition of biosynthesis. Second, other mechanisms, besides ABCA1, may play a role in cholesterol efflux, in astrocytes as in neurons. Indeed, ABCA1-independent mechanisms of apo A-I-and apo E-induced cholesterol efflux have been reported in other cell types. Data presented in Fig. 7 E, F support these hypotheses; indeed, when ABCA1 activity is inhibited by probucol, we observe a decrease in cholesterol efflux from astrocytes greater than the one observed after siRNA transfection; on the other hand, even probucol fails to completely inhibit cholesterol efflux from apo A-I, apo E, HDL, and ACM, confirming that other mechanisms are also involved.
Effect of ABCG1 and ABCG4 silencing on acceptor-mediated cholesterol efflux from astrocytes and neurons
reported an involvement of ABCA1 in facilitating cholesterol efflux from both neurons and astrocytes [28, 47] . One methodological factor that may explain these differences consists in culturing conditions; for instance, we took great care in implementing neuronal cultures with minimal astrocyte contamination (see Methods and Results). Additional differences in culturing conditions, such as the age of the cultures at the time of testing, may also be responsible for some of the discrepancies.
In contrast to apolipoproteins, we found that lipoproteins (HDL and ACM) increased cholesterol efflux with a similar potency in neurons and astrocytes (Fig. 1) reported to be expressed in glial cells but not in neurons [52] , and our present findings suggest that ABCA1 and ABCG1 are not involved in cholesterol efflux from neurons. While it is likely that a portion of lipoprotein-induced cholesterol efflux both from neurons and astrocytes may be mediated by passive diffusion, the robust cholesterol efflux induced by lipoproteins in neurons (similar to what was observed in astrocytes; Fig. 1 ), suggests the involvement of an active mechanism of cholesterol transport. We found that ABCG4, at difference with ABCA1 and ABCG1, is expressed at much higher levels in neurons than astrocytes (Fig. 2) ; furthermore, cholesterol efflux to HDL is inhibited in neurons transfected with ABCG4 siRNA but not in astrocytes (Fig. 8) , indicating that this transporter, whose expression is not affected by LXR/RXR ligands and by ethanol (Fig. 3 and 5) , is involved in lipoprotein-mediated cholesterol efflux from neurons, as also hypothesized by others [17].
In conclusion, the present study demonstrates that cholesterol efflux is differentially regulated in neurons and astrocytes. While ABCA1 and, likely, ABCG1 play an important role in cholesterol efflux from glial cells, the mechanism by which lipoproteins induce cholesterol efflux from neurons is not fully elucidated, though ABCG4 may play a role. These findings need to be kept in consideration in the development of therapeutic drugs for the treatments of diseases associated with disturbances of cholesterol homeostasis.
While in the case of ABCA1, siRNA findings were substantiated by experiments using the pharmacological inhibitor probucol, specific pharmacological inhibitors for ABCG1 and ABCG4
are not currently available. Because the efficiency of transfection in our experimental conditions is higher in astrocytes than in neurons, it is possible that the lack of an effect of ABCG1 siRNA on cholesterol efflux from neurons may be due to the fact that ABCG1 is not sufficiently downregulated in these cells. However, the upregulation of ABCA1 and ABCG1 transporters by LXR/RXR agonists and ethanol does not increase cholesterol efflux from neurons, while doing so in astrocytes, supporting the proposed hypothesis that ABCG1 may not play a role in cholesterol efflux from neurons. Finally, ABCG4 siRNA reduced cholesterol efflux in neurons but not in astrocytes; this effect was significant in spite of the fact that, also in this case, the efficiency of transfection was lower in neurons than in astrocytes, suggesting that the role of ABCG4 on cholesterol efflux from neurons may be underestimated under our experimental conditions. ABCG1 protein levels in primary cortical astrocytes and average optical density of ABCA1 and ABCG1 protein levels normalized to -actin and expressed as % of control (n=3-5). *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to control by Student's t test.
efflux was measured at the end of incubation and expressed as percent of control (n=6-9). ##, p < 0.01 compared to acceptor-matched controls by Student's t test. A: Primary rat cortical neurons were transfected with a non-target (NT siRNA), an ABCG1 specific siRNA (ABCG1 siRNA) or an ABCG4 siRNA using the i-Fect TM siRNA transfection reagent. B: Primary rat cortical astrocytes were transfected with an ABCG1 siRNA or an ABCG4 siRNA using lipofectamine RNAiMAX. Twenty-four hours after transfection, cells were labeled with 1 µCi/ml [
